



NASDAQ:VRPX

OUTSTANDING SHARES: 4,960,153

WEBSITE: www.virpaxpharma.com

LEAD PRODUCT CANDIDATES

Epoladerm™, Diclofenac Topical Metered-Dose Spray
Probudur™, Injectable Long-acting Bupivacaine
Envelta™, Endogenous Enkephalin Intranasal Spray
MMS019, High-Density Molecular Masking Spray

INTELLECTUAL PROPERTY

Orange Book-listable patents

EXECUTIVE MANAGEMENT

Anthony P. Mack, MBA, Chairman and CEO

25+ years of experience in the Pharmaceutical Industry
Founder, President and CEO of SCILEX Pharmaceuticals
Founder, President of ProSolutus Pharmaceuticals
Management and Director positions held with Purdue Pharma, Endo Pharmaceuticals and EKR Therapeutics

Jeffrey Gudin, MD, EVP, Chief Medical Officer

25 years pain management, clinician, consultant & researcher
Board certified in Pain Medicine, Anesthesiology, Addiction Medicine, Hospice and Palliative Medicine
Anesthesiology Residency and Pain Management Fellowship at Yale University School of Medicine
Faculty at the University of Miami in the Dept of Anesthesiology, Perioperative Medicine and Pain Management
Principal Investigator for NCATS/NIH for Envelta™

Gerald W. Bruce, EVP, Commercial Operations

30+ years Pharmaceutical & Medical Nutrition industry
Group Product Director, Analgesics at Johnson, and Johnson
VP, Sales at Bristol-Myers Squibb, \$1.2B in Sales
VP, Managed Markets Bristol-Myers Squibb, \$7B US
SVP, Commercial Operations, NitroMed
Vice President of Sales for Nutricia North America

Christopher M. Chipman, CPA, Chief Financial Officer

25+ years of public and private accounting experience
Managing Partner of Chipman & Chipman, LLC
CFO, Capital Gold Corporation
Senior Accountant, Grant Thornton, LLP
Audit Examiner, Wells Fargo

Sheila A. Mathias, PhD, JD, MBA, Chief Scientific Officer

20+ years Pharmaceutical industry experience
Expertise in Global Regulatory & Drug development Therapeutic areas, include pain and dermatology
Senior Director Global Regulatory Affairs at Sun Pharma
Leadership roles at Merck US and Aventis Pharmaceuticals B.S. in Zoology; PhD in Neurophysiology

BOARD OF DIRECTORS

Anthony P. Mack, MBA, Chairman and CEO

Jeffrey Gudin, MD, EVP, Chief Medical Officer

Eric Floyd, PhD, Chairman, Compensation Committee and Scientific and Technology Committee

Jerrold Sendrow, CFP, Chairman, Audit Committee

Thani Jambulingam, PhD, Chairman, Corporate Governance

Gary S. Jacob, PhD., Co-Founder and Former CEO, Synergy Pharmaceuticals; Former CEO, Immuron, Inc.

Vanila M. Singh, MD, MACM, Former CMO, US Department of Health and Human Services

BUSINESS SUMMARY

Virpax® Pharmaceuticals is a publicly held company (NASDAQ:VRPX) focused on developing and commercializing non-addictive pain products. Virpax has global rights for three unique, patented delivery technologies, including a Metered-Dose Topical Spray Film Delivery Technology for acute musculoskeletal pain, an injectable "local anesthetic" Liposomal Hydro-Gel Technology for postoperative pain management, and a proprietary intranasal Molecular Envelope Technology (MET) for the management of chronic pain, cancer pain and the treatment of Post-Traumatic Stress Disorder (PTSD). Simultaneously, Virpax is developing its intranasal MET delivery system (MMS019) to help prevent viral spread, including influenza and SARS-CoV-2. MMS019 has also demonstrated reduced viral brain load in our animal trial. Future product candidates for development will include treatments for neurological disorders.

TECHNOLOGY

- Epoladerm™'s metered-dose spray film technology platform administers a therapeutic dose of diclofenac for safe drug absorption through the skin over 24 hours without the messy handling of gels that must be rubbed onto the skin and the adhesion concerns of topical patches.
- Probudur™ uses a liposomal delivery system with large multi-vesicular vesicles (LMVVs) encapsulating local anesthetic bupivacaine. These LMVVs are embedded in hydrogel beads to form a lipogel. The system delivery is intended to provide improved onset, duration, and peak performance.
- Envelta™ uses a preassembled delivery device and cartridge to propel the enkephalin formulation through the nose to the brain via the olfactory route. The (MET) carries the drug across the blood brain barriers to delta receptors to promptly suppress moderate to severe pain without the opioid side effects.
- MMS019 is a mucoadhesive in nature and is being studied to inhibit viral production and may prevent SARS-CoV-2 and influenza from binding to cells inside of the nose thereby preventing infection for up to 24 hours.

RECENT PRESS RELEASES *(Headlines and Excerpts)*

[Virpax Engages Torreya to Advise on Global Partnering Efforts](#)

April 22, 2021 / Virpax® today announced the Company has engaged Torreya Capital to serve as the exclusive financial advisor for the Company's partnering and licensing efforts in strategic global markets.

[Virpax's MMS019 Reduced Nasal and Brain Viral Load in Animal Study](#)

April 19, 2021 / Virpax® today announced the results of an animal study model for MMS019, its anti-viral product candidate for respiratory viruses.

[Virpax Announces Results of Probudur \(TM\) in Animal Study](#)

April 5, 2021 / ...The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur™), at 10 times more than free bupivacaine, showed no signs of nerve damage. Further, nerves injected with Probudur™ showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage.

[Virpax Begins IND Enabling Studies of Envelta™](#)

February 23, 2021 / Virpax® today announced that according to the Cooperative Research and Development Agreement ("CRADA") entered into between Virpax and the National Center for Advancing Translational Sciences ("NCATS"), an institute/center of the National Institutes of Health ("NIH"), U.S. Department of Health and Human Services, the NCATS has begun the Investigational New Drug ("IND") enabling studies of Envelta™ to support Virpax's future application for clearance from the FDA to initiate its first-in-human ("FIH") clinical trials.

CONTACT INFORMATION

Investor Relations

Betsy Brod

Affinity Growth Advisors

betsy.brod@affinitygrowth.com

(212) 661-2231

Christopher M. Chipman, CPA

Chief Financial Officer

cchipman@virpaxpharma.com

(610) 727-4597